Nachrichten zur Sarepta Therapeutics Inc. Aktie

• Sarepta Therapeutics erhält erweiterte FDA-Zulassung • Zusammenarbeit mit Roche bei Medikament gegen Muskelschwund • Sarepta Therapeutics-Aktie mit Kurssprung …

The Nasdaq and S&P 500 fell from record highs Thursday. Sarepta Therapeutics surged Friday on FDA approval.…

The Dow, S&P 500, and Nasdaq were little changed at midday Friday, June 21, 2024 as reports showed existing home…

Kulmbach (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse vom Online-Anlegermagazin "Der Aktionär": Michel Doepke von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die des…

Sarepta Therapeutics surges 36% after-hours following expanded FDA approval…

…

Sarepta Therapeutics gains as Pfizer failure removes overhang…

London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays: Gena Wang, Analystin von Barclays, nimmt in einer aktuellen Aktienanalyse die Aktie von Sarepta…

…

Mizuho raises Sarepta Therapeutics stock target on FDA hopes…

SRPT earnings call for the period ending March 31, 2024.…

…

…

…

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

The upcoming regulatory decision on its latest drug could be big.…

UBS raises Sarepta Therapeutics shares target on label outlook…

SRPT earnings call for the period ending December 31, 2023.…

…

The companys hyperfocus on its core area could continue to be highly lucrative.…